|
Cytokinetics Announces Clinical Trials Data Relating to Ispinesib to Be Presented at the 2008 ASCO Breast Cancer Symposium
(Marketwire Via Acquire Media NewsEdge) SOUTH SAN FRANCISCO, CA, August 29 / MARKET WIRE/ --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data from an ongoing Phase I/II clinical trial
of ispinesib are scheduled to be presented as a poster presentation at the
2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium,
to be held September 5-7, 2008 at the Hilton Washington in Washington, DC.
In June 2008, as part of a poster session at the ASCO Annual Meeting,
Cytokinetics announced interim data from the Phase I portion of its ongoing
Phase I/II clinical trial of ispinesib, a novel kinesin spindle protein
(KSP) inhibitor, administered as monotherapy as a first-line treatment in
chemotherapy-na?ve patients with locally advanced or metastatic breast
cancer. The authors concluded that preliminary data suggest that ispinesib
is well-tolerated when dosed on days 1 and 15 every 28 days at doses up to
12 mg/m2. Results from additional patients enrolled in the ongoing Phase
I, dose-escalation portion of this clinical trial are scheduled to be
presented the 2008 ASCO Breast Cancer Symposium.
Poster Presentation at ASCO Breast Cancer Symposium:
Abstract #192: "A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein
(KSP) Inhibitor, Dosed Every Two Weeks in Patients (pts) with Locally
Advanced (LA) or Metastatic Breast Cancer (MBC) Previously Untreated with
Chemotherapy (CT) for Metastatic Disease or Recurrence." (Poster
Presentation on Friday, September 5, 2008, during the General Poster
Session, 5:30 pm - 6:45 pm Eastern Time). The poster will be found in the
Exhibit Hall at poster board #A50 and presented by Henry Gomez, MD from
Instituto Nacional de Enfermedades Neoplasicas (INEN) in Lima, Peru.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule drugs that may
address areas of significant unmet clinical needs. Cytokinetics'
cardiovascular disease program is focused to cardiac myosin, a motor
protein essential to cardiac muscle contraction. Cytokinetics' lead
compound from this program, CK-1827452, a novel small molecule cardiac
myosin activator, entered Phase II clinical trials for the treatment of
heart failure in 2007. Under a strategic alliance established in 2006,
Cytokinetics and Amgen Inc. are performing joint research focused on
identifying and characterizing activators of cardiac myosin as back-up and
follow-on potential drug candidates to CK-1827452. Amgen has obtained an
option for an exclusive license to develop and commercialize CK-1827452,
subject to Cytokinetics' development and commercial participation rights.
Cytokinetics' cancer program is focused on mitotic kinesins, a family of
motor proteins essential to cell division. Under a strategic alliance
established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting
research and development activities focused on the potential treatment of
cancer. Cytokinetics is developing two novel drug candidates that have
arisen from this program, ispinesib and SB-743921, each a novel inhibitor
of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is
sponsoring a Phase I/II clinical trial of ispinesib as monotherapy as a
first-line treatment in chemotherapy-na?ve patients with locally advanced
or metastatic breast cancer. In addition, Cytokinetics is conducting a
Phase I/II trial of SB-743921 in patients with non-Hodgkin or Hodgkin
lymphomas. GSK has obtained an option for the joint development and
commercialization of ispinesib and SB-743921. Cytokinetics and GSK are
conducting collaborative research activities directed to the mitotic
kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E
inhibitor, is being developed under the strategic alliance by GSK; GSK
began a Phase I clinical trial with GSK-923295 in 2007. In April 2008,
Cytokinetics announced the selection of a potential drug candidate directed
towards skeletal muscle contractility which may be developed as a potential
treatment for skeletal muscle weakness associated with neuromuscular
diseases or other conditions. All of these drug candidates and potential
drug candidates have arisen from Cytokinetics' research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements relating to
Cytokinetics' research and development programs, including planned
presentations relating to clinical trial results, and the properties and
potential benefits of Cytokinetics' drug candidates and potential drug
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to various risks
and uncertainties, including, but not limited to, potential difficulties or
delays in the development, testing, regulatory approval or production of
Cytokinetics' drug candidates that could slow or prevent clinical
development or product approval, including risks that current and past
results of clinical trials or preclinical studies may not be indicative of
future clinical trials results, patient enrollment for clinical trials may
be difficult or delayed, Cytokinetics' drug candidates may have adverse
side effects or inadequate therapeutic efficacy, the U.S. Food and Drug
Administration or foreign regulatory agencies may delay or limit
Cytokinetics' or its partners' ability to conduct clinical trials, and
Cytokinetics may be unable to obtain or maintain patent or trade secret
protection for its intellectual property; Cytokinetics may incur
unanticipated research and development and other costs or be unable to
obtain additional financing necessary to conduct development of its
products; standards of care may change and others may introduce products or
alternative therapies for the treatment of indications Cytokinetics' drug
candidates and potential drug candidates may target; and risks and
uncertainties relating to the timing and receipt of payments from
Cytokinetics' partners, including milestones and royalties on future
potential product sales under its collaboration agreements with such
partners. For further information regarding these and other risks related
to Cytokinetics' business, investors should consult Cytokinetics' filings
with the Securities and Exchange Commission.
Contacts:
Scott R. Jordan (Media)
Director, Corporate Development
(650) 624-3000
Christopher S. Keenan (Investors)
Director, Investor Relations
(650) 624-3000
Copyright ? 2008 Marketwire
[ Back To TMCnet.com's Homepage ]
|
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, February 2-4, 2009. Miami, Florida.
